奥密克戎变异株 BA.2.86 对 SARS-CoV-2 的中和逃逸
Neutralization escape by SARS-CoV-2 Omicron subvariant BA.2.86.
机构信息
Beth Israel Deaconess Medical Center, Boston, MA, USA.
Los Alamos National Laboratories, Santa Fe, NM, USA.
出版信息
Vaccine. 2023 Nov 13;41(47):6904-6909. doi: 10.1016/j.vaccine.2023.10.051. Epub 2023 Oct 21.
Abstract
The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) variant BA.2.86 has over 30 mutations in spike compared with BA.2 and XBB.1.5, which raised the possibility that BA.2.86 might evade neutralizing antibodies (NAbs) induced by vaccination or infection. In this study, we show that NAb titers are substantially lower to BA.2.86 compared with BA.2 but are similar or slightly higher than to other current circulating variants, including XBB.1.5, EG.5.1, and FL.1.5.1. Moreover, NAb titers against all these variants were higher in vaccinated individuals with a history of XBB.1.5 infection compared with vaccinated individuals with no history of XBB.1.5 infection, suggesting the potential utility of the monovalent XBB.1.5 mRNA boosters.
摘要
严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 的变异株 BA.2.86 与 BA.2 和 XBB.1.5 相比，在刺突蛋白上有超过 30 个突变，这增加了 BA.2.86 可能逃避疫苗接种或感染诱导的中和抗体 (NAb) 的可能性。在这项研究中，我们表明，与 BA.2 相比，针对 BA.2.86 的 NAb 滴度显著降低，但与其他当前流行的变异株（包括 XBB.1.5、EG.5.1 和 FL.1.5.1）相似或略高。此外，与没有 XBB.1.5 感染史的接种者相比，有 XBB.1.5 感染史的接种者对所有这些变异株的 NAb 滴度更高，这表明单价 XBB.1.5 mRNA 加强针的潜在效用。
相似文献
1
Neutralization escape by SARS-CoV-2 Omicron subvariant BA.2.86.奥密克戎变异株 BA.2.86 对 SARS-CoV-2 的中和逃逸
Vaccine. 2023 Nov 13;41(47):6904-6909. doi: 10.1016/j.vaccine.2023.10.051. Epub 2023 Oct 21.
2
An mRNA vaccine encoding the SARS-CoV-2 Omicron XBB.1.5 receptor-binding domain protects mice from the JN.1 variant.一种编码严重急性呼吸综合征冠状病毒2（SARS-CoV-2）奥密克戎XBB.1.5受体结合结构域的信使核糖核酸（mRNA）疫苗可保护小鼠免受JN.1变体的感染。
EBioMedicine. 2025 Jun 6;117:105794. doi: 10.1016/j.ebiom.2025.105794.
3
Neutralizing antibody response to SARS-CoV-2 bivalent mRNA vaccine in SIV-infected rhesus macaques: Enhanced immunity to XBB subvariants by two-dose vaccination.SIV 感染恒河猴中针对 SARS-CoV-2 二价 mRNA 疫苗的中和抗体反应：两剂接种增强对 XBB 亚变种的免疫力。
J Med Virol. 2024 Mar;96(3):e29520. doi: 10.1002/jmv.29520.
4
Immunogenicity of monovalent and multivalent subunit vaccines against SARS-CoV-2 variants in mice with divergent vaccination history.具有不同疫苗接种史的小鼠中，单价和多价亚单位疫苗针对新冠病毒变异株的免疫原性。
Microbiol Spectr. 2025 Jul 17:e0290724. doi: 10.1128/spectrum.02907-24.
5
Mucosal and Serum Neutralization Immune Responses Elicited by COVID-19 mRNA Vaccination in Vaccinated and Breakthrough-Infection Individuals: A Longitudinal Study from Louisville Cohort.COVID-19 mRNA疫苗接种在接种者和突破性感染个体中引发的黏膜和血清中和免疫反应：来自路易斯维尔队列的纵向研究
Vaccines (Basel). 2025 May 24;13(6):559. doi: 10.3390/vaccines13060559.
6
SARS-CoV-2 infection triggers more potent antibody-dependent cellular cytotoxicity (ADCC) responses than mRNA-, vector-, and inactivated virus-based COVID-19 vaccines.SARS-CoV-2 感染引发的抗体依赖细胞介导的细胞毒性（ADCC）反应强于基于 mRNA、载体和灭活病毒的 COVID-19 疫苗。
J Med Virol. 2024 Mar;96(3):e29527. doi: 10.1002/jmv.29527.
7
Immunogenicity and safety of a monovalent Omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine in previously unvaccinated, SARS-CoV-2 seropositive participants: Primary day-28 analysis of a phase 2/3 open-label study.一种单价奥密克戎XBB.1.5 SARS-CoV-2重组刺突蛋白疫苗在既往未接种过疫苗、SARS-CoV-2血清阳性参与者中的免疫原性和安全性：一项2/3期开放标签研究的第28天初步分析
Vaccine. 2025 May 10;55:127046. doi: 10.1016/j.vaccine.2025.127046. Epub 2025 Apr 2.
8
Differential immunity induced by Omicron sublineages in naïve and vaccine breakthrough infections.奥密克戎亚谱系在初次感染和疫苗突破性感染中诱导的差异性免疫。
Sci Rep. 2025 Jul 3;15(1):23718. doi: 10.1038/s41598-025-07702-2.
9
Determinants of antibody levels and protection against omicron BQ.1/XBB breakthrough infection.抗体水平及预防奥密克戎BQ.1/XBB突破性感染的决定因素
Commun Med (Lond). 2025 Jun 20;5(1):243. doi: 10.1038/s43856-025-00943-2.
10
Exposure of progressive immune dysfunction by SARS-CoV-2 mRNA vaccination in patients with chronic lymphocytic leukemia: A prospective cohort study.SARS-CoV-2 mRNA 疫苗接种在慢性淋巴细胞白血病患者中引发渐进性免疫功能障碍：一项前瞻性队列研究。
PLoS Med. 2023 Jun 29;20(6):e1004157. doi: 10.1371/journal.pmed.1004157. eCollection 2023 Jun.
引用本文的文献
1
SARS-CoV-2 Pneumonia: Advances in Diagnosis and Treatment.严重急性呼吸综合征冠状病毒2型肺炎：诊断与治疗进展
Microorganisms. 2025 Jul 31;13(8):1791. doi: 10.3390/microorganisms13081791.
2
Conformational Dynamics and Binding Interactions of SARS-CoV-2 Spike Protein Variants: Omicron, XBB.1.9.2, and EG.5.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）刺突蛋白变体的构象动力学与结合相互作用：奥密克戎、XBB.1.9.2和EG.5
J Chem Inf Model. 2025 Jul 11. doi: 10.1021/acs.jcim.5c00308.
3
RSV F evolution escapes some monoclonal antibodies but does not strongly erode neutralization by human polyclonal sera.呼吸道合胞病毒F蛋白的进化能逃避一些单克隆抗体，但不会严重削弱人多克隆血清的中和作用。
J Virol. 2025 Jul 22;99(7):e0053125. doi: 10.1128/jvi.00531-25. Epub 2025 Jul 3.
4
Immune evasion, infectivity, and membrane fusion of the SARS-CoV-2 JN.1 variant.新型冠状病毒JN.1变体的免疫逃逸、传染性和膜融合
Virol J. 2025 May 24;22(1):162. doi: 10.1186/s12985-025-02737-3.
5
Comparative analysis of replication and immune evasion among SARS-CoV-2 subvariants BA.2.86, JN.1, KP.2, and KP.3.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）亚型BA.2.86、JN.1、KP.2和KP.3的复制与免疫逃逸比较分析
mBio. 2025 Apr 29:e0350324. doi: 10.1128/mbio.03503-24.
6
RSV F evolution escapes some monoclonal antibodies but does not strongly erode neutralization by human polyclonal sera.呼吸道合胞病毒融合蛋白（RSV F）的进化能逃避一些单克隆抗体，但不会严重削弱人多克隆血清的中和作用。
bioRxiv. 2025 Mar 11:2025.03.11.642476. doi: 10.1101/2025.03.11.642476.
7
The XBB.1.5 mRNA booster vaccine does not significantly increase the percentage of XBB.1.5 mono-reactive T cells.XBB.1.5 mRNA加强疫苗不会显著增加XBB.1.5单反应性T细胞的百分比。
Front Immunol. 2025 Mar 12;16:1513175. doi: 10.3389/fimmu.2025.1513175. eCollection 2025.
8
Role of glycosylation mutations at the N-terminal domain of SARS-CoV-2 XEC variant in immune evasion, cell-cell fusion, and spike stability.新型冠状病毒XEC变异株N端结构域糖基化突变在免疫逃逸、细胞间融合及刺突蛋白稳定性中的作用
J Virol. 2025 Apr 15;99(4):e0024225. doi: 10.1128/jvi.00242-25. Epub 2025 Mar 26.
9
SARS-CoV-2 Fusion Peptide-Directed Antibodies Elicited by Natural Infection Mediate Broad Sarbecovirus Neutralization.自然感染引发的针对严重急性呼吸综合征冠状病毒2融合肽的抗体介导广泛的Sarbecovirus中和作用。
medRxiv. 2025 Mar 5:2025.03.01.25323010. doi: 10.1101/2025.03.01.25323010.
10
Designed mosaic nanoparticles enhance cross-reactive immune responses in mice.设计的镶嵌纳米颗粒增强小鼠的交叉反应性免疫反应。
Cell. 2025 Feb 20;188(4):1036-1050.e11. doi: 10.1016/j.cell.2024.12.015. Epub 2025 Jan 23.
本文引用的文献
1
Antigenicity and receptor affinity of SARS-CoV-2 BA.2.86 spike.SARS-CoV-2 BA.2.86 刺突蛋白的抗原性和受体亲和力。
Nature. 2023 Dec;624(7992):639-644. doi: 10.1038/s41586-023-06750-w. Epub 2023 Oct 23.
2
Less neutralization evasion of SARS-CoV-2 BA.2.86 than XBB sublineages and CH.1.1.与 XBB 亚系和 CH.1.1 相比，SARS-CoV-2 BA.2.86 的中和逃逸能力较低。
Emerg Microbes Infect. 2023 Dec;12(2):2271089. doi: 10.1080/22221751.2023.2271089. Epub 2023 Oct 26.
3
Antigenicity and infectivity characterisation of SARS-CoV-2 BA.2.86.新型冠状病毒BA.2.86的抗原性和感染性特征
Lancet Infect Dis. 2023 Nov;23(11):e457-e459. doi: 10.1016/S1473-3099(23)00573-X. Epub 2023 Sep 19.
4
Transmissibility, infectivity, and immune evasion of the SARS-CoV-2 BA.2.86 variant.严重急性呼吸综合征冠状病毒2型BA.2.86变体的传播性、传染性和免疫逃逸
Lancet Infect Dis. 2023 Nov;23(11):e460-e461. doi: 10.1016/S1473-3099(23)00575-3. Epub 2023 Sep 18.
5
Project NextGen - Defeating SARS-CoV-2 and Preparing for the Next Pandemic.下一代项目——战胜新冠病毒并为下一次大流行做准备。
N Engl J Med. 2023 Aug 31;389(9):773-775. doi: 10.1056/NEJMp2307867. Epub 2023 Jul 26.
6
Durability of Bivalent Boosters against Omicron Subvariants.二价加强针针对奥密克戎亚变体的持久性。
N Engl J Med. 2023 May 11;388(19):1818-1820. doi: 10.1056/NEJMc2302462. Epub 2023 Apr 12.
7
Substantial Neutralization Escape by SARS-CoV-2 Omicron Variants BQ.1.1 and XBB.1.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）奥密克戎变种BQ.1.1和XBB.1的显著中和逃逸
N Engl J Med. 2023 Feb 16;388(7):662-664. doi: 10.1056/NEJMc2214314. Epub 2023 Jan 18.
8
Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5.严重急性呼吸综合征冠状病毒2型奥密克戎亚变体BA.2.12.1、BA.4和BA.5的中和逃逸
N Engl J Med. 2022 Jul 7;387(1):86-88. doi: 10.1056/NEJMc2206576. Epub 2022 Jun 22.
9
Antibody evasion properties of SARS-CoV-2 Omicron sublineages.SARS-CoV-2 奥密克戎亚谱系的抗体逃逸特性。
Nature. 2022 Apr;604(7906):553-556. doi: 10.1038/s41586-022-04594-4. Epub 2022 Mar 3.
10
Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite.针对刺突 N 端结构域的强效 SARS-CoV-2 中和抗体靶向单一超位点。
Cell Host Microbe. 2021 May 12;29(5):819-833.e7. doi: 10.1016/j.chom.2021.03.005. Epub 2021 Mar 12.
Zotero 插件